ACEI continuation — Competitive Intelligence Brief

ACEI continuation (ACEI continuation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

marketed ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule

Target snapshot

ACEI continuation (ACEI continuation) — University of Nebraska. ACEI continuation refers to the ongoing use of angiotensin-converting enzyme inhibitors to block the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and lowering blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACEI continuation TARGET	ACEI continuation	University of Nebraska	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)
Vasotec	enalapril	Merck & Co.	marketed	ACE inhibitor	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1985-12-24
Captopril Tablets	Captopril Tablets	Ain Shams University	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)
ACE Inhibitors and Diuretics	ACE Inhibitors and Diuretics	The University of Texas Health Science Center, Houston	marketed	ACE inhibitor + diuretic combination	Angiotensin-converting enzyme (ACE); various diuretic targets depending on class (e.g., loop of Henle, distal convoluted tubule)
Perindopril plus Amlodipine	Perindopril plus Amlodipine	University of Abuja	marketed	ACE inhibitor + Calcium channel blocker combination	ACE (angiotensin-converting enzyme) and L-type calcium channels
Perindopril + Indapamide	Perindopril + Indapamide	Centre for Chronic Disease Control, India	marketed	ACE inhibitor + thiazide-like diuretic combination	Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter
Matching placebo to Ramipril	Matching placebo to Ramipril	Novartis	marketed	Placebo (matching formulation for ACE inhibitor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

1. Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
2. Bioprojet · 2 drugs in this class
3. Ain Shams University · 2 drugs in this class
4. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
5. Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
6. Children's Hospital of Fudan University · 1 drug in this class
7. Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
9. Ethicare GmbH · 1 drug in this class
10. Ace Cells Lab Limited · 1 drug in this class